Project Grant K22HL166368
Award Date
7/5/25
Completion Date
5/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Northwestern University provides $798,958 to conduct research on the molecular mechanisms underlying the link between primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) after lung transplantation. The key objectives are to: 1) Determine whether activation of the integrated stress response (ISR) in the alveolar epithelium impairs repair after...
This $2,803,961 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research effort to investigate the mechanisms underlying primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The research team at Northwestern University will conduct four interrelated projects to better understand the role of lung-restricted alloantibodies,...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $2,241,717 to the University of Pittsburgh to conduct research on the role of plasma cells in chronic rejection after lung transplantation. The key goals are to: 1) Provide a comprehensive map of B and plasma cell gene expression, population heterogeneity, and temporal dynamics in chronically rejected lungs after transplantation; and 2) Mechanistically interrogate...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $1,584,308 Project Grant to Northwestern University to conduct research on complementary pathways of necroptosis in recipient and donor lung tissue that drive primary lung allograft dysfunction. The 5-year grant, beginning September 1, 2024, aims to comprehensively understand and pharmacologically target the necroptotic pathways in both the donor and recipient...
This federal Project Grant award of $301,840 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project titled "EPIC-LT: ELIMINATING PGD THROUGH INHIBITION OF CCR5 IN LUNG TRANSPLANTATION". The primary objectives are to: Measure the feasibility of recruiting lung transplant recipients for a pilot clinical trial of CCR5 inhibition to prevent primary graft dysfunction (PGD). Assess the safety and tolerability of the...
This $392,882 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by Dr. Brandon Smith at The Johns Hopkins University to address racial disparities in chronic lung disease (CLD) for preterm infants. The key objectives are to: 1) characterize medical and social determinant profiles of preterm infants with CLD and identify high-risk groups, 2) describe the lived experiences of...
This Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research at the University of Iowa to investigate mesenchymal cell plasticity and signaling in lung regeneration. The goal is to develop a comprehensive understanding of the progenitor cells and their functions after severe lung injury, as well as how they signal and interact with other cells within the injured alveolar niche. The research aims...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,411,136 to characterize circadian rhythms in organ donors and identify mechanisms by which donor and recipient circadian clocks affect transplant acceptance. The goal is to pioneer the study of biological rhythms in organ donors and examine how regulation of donor neutrophil glycolysis by the master clock gene BMAL1 contributes to lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $189,000 to the University of Colorado-Denver to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in pulmonary fibrosis following acute lung injury and acute respiratory distress syndrome (ARDS). The 2-year research project aims to elucidate the mechanisms by which ALDH2 impacts fibrogenesis in lung cells and evaluate the...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...